Press Releases & Presentations

Press Releases & Presentations

Date Title and Summary Additional Formats
Toggle Summary Accelr8 Attracts Up To $35 Million Private Equity Investment
Private equity firm buys common stock with warrants, brings long track record of success in medical technology business development. Read more
View HTML
Toggle Summary Accelr8 Announces Development Expansion for Blood-Based Diagnostic Tests
Adding BACcel&#8482 test panel for multiple pathogens and multiple drug resistance types for positive blood cultures. Adding BAC-Xtrax&#8482 automated 10-minute specimen preparation, also potential as a stand-alone product. Read more
View HTML
Toggle Summary Accelr8 Announces Interim Plan and Advanced Studies
Transition with collaboration, Proof of Concept begins with complex Gram-negative bacilli in blood culture Read more
View HTML
Toggle Summary Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New Patent
License renewal and new patent reflect further expansion in the medical diagnostics market segment. Read more
View HTML
Toggle Summary Accelr8 Announces Results in Award-Winning Presentation for Rapid Diagnostics with ICU Specimens
Presented at 51st ICAAC, Chicago Read more
View HTML
Toggle Summary Accelr8 Announces Continuation and Expansion of BACcel™ Development Collaboration
Favorable data review followed by project to install newest version of BACcel&#8482 automation in collaborator's microbiology lab. Read more
View HTML
Toggle Summary Accelr8 to Receive Award for ICAAC Presentation
ICAAC's Program Committee recognizes Accelr8's BACcel&#8482 rapid diagnostic system as a significant advance in Clinical Microbiology. Read more
View HTML
Toggle Summary Accelr8 Announces Continuation of BACcel™ Collaboration
Accelr8 extends current agreement to allow time for data evaluation. Intent to reach terms by July 31. Read more
View HTML
Toggle Summary Accelr8 4-Hour Test Identifies New Drug-Resistant "Staph" (hVISA) Undetectable by Hospital Labs
Accelr8 presented results of two studies at ASM 2011 in New Orleans. One reported results with a new 4-hour hVISA test for a threatening new type of Staph resistance. The second study screened ICU patient specimens to successfully detect and identify three leading species of potentially resistant pathogens in 4 hours, directly from specimen. The 3-organism test included the two most important resistance types for each species. Read more
View HTML
Toggle Summary Accelr8 Announces Initial Results from ICU Pilot Clinical Study for Same-Day, Multi-Organism, Multi-Resistance Diagnostics Presented at ATS
Initial data from pilot study show strong positive results for the BACcel&#8482 rapid system. Read more
View HTML
:

Day High:
Day Low:  
Volume:    

Copyright Nasdaq. Minimum 15 minutes delayed.


Want to receive investor-related news and updates?

Join our mailing list

Other updates